dc.creator | García, Mónica C. | es |
dc.creator | Calderón Montaño, José Manuel | es |
dc.creator | Rueda Rueda, Manuela | es |
dc.creator | Longhi, Marcela | es |
dc.creator | Rabasco Álvarez, Antonio María | es |
dc.creator | López Lázaro, Miguel | es |
dc.creator | Prieto Dapena, Francisco | es |
dc.creator | González Rodríguez, María Luisa | es |
dc.date.accessioned | 2022-11-14T09:35:25Z | |
dc.date.available | 2022-11-14T09:35:25Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | García, M.C., Calderón Montaño, J.M., Rueda Rueda, M., Longhi, M., Rabasco Álvarez, A.M., López Lázaro, M.,...,González Rodríguez, M.L. (2022). pH-temperature dual-sensitive nucleolipid-containing stealth liposomes anchored with PEGylated AuNPs for triggering delivery of doxorubicin. International Journal of Pharmaceutics, 619, 121691. https://doi.org/10.1016/j.ijpharm.2022.121691. | |
dc.identifier.issn | 0378-5173 | es |
dc.identifier.uri | https://hdl.handle.net/11441/139384 | |
dc.description.abstract | Liposomes (Lip) are useful nanocarriers for drug delivery and cancer nanomedicine because of their ability to efficiently encapsulate drugs with different physical and chemical properties. The pH gradient between normal and tumoral tissues, and their rapid metabolism that induces hyperthermia encourage the development of pH- and thermo-sensitive Lip for delivering anticancer drugs. Nucleolipids have been studied as scaffolding material to prepare Lip, mainly for cancer therapy. Herein, we report for the first time the use of 1,2-dipalmitoyl-sn-glycero-3-(cytidine diphosphate) (DG-CDP) to develop pH/thermo-sensitive nucleolipid-containing stealth Lip stabilized by combination with 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and cholesterol, anchored with NH2-PEGylated gold nanoparticles (PEG-AuNPs, 15 nm) for triggering delivery of doxorubicin (Dox). The optimal composition of DPPC, DG-CDP and cholesterol (94:3:3) was established by Langmuir isotherms. Unloaded and Dox-loaded Lip and AuNPs-Lip exhibited nano-scale sizes (415–650 nm), acceptable polydispersity indexes (<0.33), spherical shapes, and negative Z-potential (−23 to −6.6 mV) due to the phosphate groups of DG-CDP, which allowed the anchoring with positively charged AuNPs. High EE% were achieved (>78%) and although efficient control in the Dox release towards different receptor media was observed, the release of Dox from PEG-AuNPs-Lip-Dox was significantly triggered at acidic pH and hyperthermia conditions, demonstrating its responsiveness to both stimuli. Dox-loaded Lip showed high cytotoxic activity against MDA-MB-231 breast cancer cells and SK-OV-3 ovarian cancer cells, suggesting that Dox was released from these nanocarriers over time. Overall, the liposomal formulations showed promising properties as stimuli-responsive nanocarriers for cancer nanomedicine, with prospects for hyperthermia therapy. | es |
dc.description.sponsorship | Ministerio de Ciencia e Innovación de España-CTQ2014-57515-C2-1 | es |
dc.description.sponsorship | Junta de Andalucía-FQM202 y CTS214 | es |
dc.description.sponsorship | Universidad de Sevilla-PPVI | es |
dc.format | application/pdf | es |
dc.format.extent | 13 p. | es |
dc.language.iso | eng | es |
dc.publisher | Elsevier | es |
dc.relation.ispartof | International Journal of Pharmaceutics, 619, 121691. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Thermo-responsive liposomes | es |
dc.subject | pH-responsive liposomes | es |
dc.subject | Drug delivery | es |
dc.subject | Gold nanoparticles | es |
dc.subject | Langmuir monolayers | es |
dc.subject | Anticancer activity | es |
dc.title | pH-temperature dual-sensitive nucleolipid-containing stealth liposomes anchored with PEGylated AuNPs for triggering delivery of doxorubicin | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Farmacología | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Farmacia y Tecnología Farmacéutica | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Química Física | es |
dc.relation.projectID | CTQ2014-57515-C2-1 | es |
dc.relation.projectID | FQM202 | es |
dc.relation.projectID | CTS214 | es |
dc.relation.projectID | US-PPVI | es |
dc.relation.publisherversion | https://doi.org/10.1016/j.ijpharm.2022.121691 | es |
dc.identifier.doi | 10.1016/j.ijpharm.2022.121691 | es |
dc.contributor.group | Universidad de Sevilla. FQM202: Electroquímica Fundamental y Aplicada a Farmacia | es |
dc.contributor.group | Universidad de Sevilla. CTS214: Sistemas de Liberación Controlada de Medicamentos | es |
dc.journaltitle | International Journal of Pharmaceutics | es |
dc.publication.volumen | 619 | es |
dc.publication.initialPage | 121691 | es |
dc.contributor.funder | Ministerio de Ciencia e Innovación (MICIN). España | es |
dc.contributor.funder | Junta de Andalucía | es |
dc.contributor.funder | Universidad de Sevilla | es |